Evidence map›Paper›PMID 33230439›Full record

ArticleMolecular therapy. Nucleic acids2020

miR-499 rs3746444 and miR-196a-2 rs11614913 Are Associated with the Risk of Glioma, but Not the Prognosis.

Si Yang, Yi Zheng, Linghui Zhou, Jing Jin, Yujiao Deng, Jia Yao, Pengtao Yang, Li Yao, Ying Wu, Zhen Zhai and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Effect ofTechnology in cancer research & treatment
    Pooled it
  2. Article
  3. Article
  4. Journal of Cancer · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Genetic Variants ofGenes · 2022
    Article
  9. Review
  10. Article
  11. The Genetic Changes of Hepatoblastoma.Frontiers in oncology · 2021
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Si YangDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Yi ZhengDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Linghui ZhouDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Jing JinDepartment of Neurosurgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Yujiao DengDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Jia YaoDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Pengtao YangDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Li YaoDepartment of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Ying WuDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhen ZhaiDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Na LiDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Lijuan LyuDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhijun DaiDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhejiang University · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies of correlations of microRNA (miR)-499 rs3746444 and miR-196a-2 rs11614913 polymorphisms with glioma risk have yielded inconsistent results. In this study, relationships between these two polymorphisms and glioma risk and survival were evaluated. In total, 605 patients and 1,300 controls were genotyped. rs3746444 increased glioma risk in five genetic models (GA versus AA, odds ratio [OR], 95% confidence interval [CI] = 1.31 [1.05-1.66], p = 0.02; GG versus AA, OR [95% CI] = 10.70 [6.13-18.69], p < 0.0001; GA + GG versus AA, OR [95% CI] = 1.82 [1.47-2.24], p < 0.0001; GG versus AA + GA, OR [95% CI] = 9.99 [5.74-17.40], p < 0.0001; G versus A, OR [95% CI] = 2.18 [1.82-2.60], p < 0.0001). rs11614913 decreased glioma risk in a recessive model (OR [95% CI] = 0.79 [0.64-0.97], p = 0.03). No relationships between either SNP and survival were found. rs3746444 in the miR-499 seed region could affect target recognition. Bioinformatics analyses indicated that miR-499 rs3746444 is involved in various biological processes and pathways, including "cell adhesion molecule binding," "positive regulation of catabolic process," "NF-kappa B pathway," and "PI3K-Akt pathway," by targeting mRNAs. Our results suggested that miR-499 rs3746444 and miR-196a-2 rs11614913 have crucial roles in glioma susceptibility.

Indexed as

gliomamiR-196a-2miR-499single nucleotide polymorphismsurvivalsusceptibility

Identifiers

PMID33230439
PMCPMC7527625
OpenAlexW3081591950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.